Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling

ABSTRACT Metabolic dysfunction is a hallmark of cardiac hypertrophy and heart failure. During cardiac failure, the metabolism of cardiomyocyte switches from fatty acid oxidation to glycolysis. However, the roles of key metabolic enzymes in cardiac hypertrophy are not understood fully. Here in the present work, we identified Aldolase A (AldoA) as a core regulator of cardiac hypertrophy. The mRNA and protein levels of AldoA were significantly up‐regulated in transverse aortic constriction (TAC)‐ and isoproterenol (ISO)‐induced hypertrophic mouse hearts. Overexpression of AldoA in cardiomyocytes promoted ISO‐induced cardiomyocyte hypertrophy, whereas AldoA knockdown repressed cardiomyocyte hypertrophy. In addition, adeno‐associated virus 9 (AAV9)‐mediated in vivo knockdown of AldoA in the hearts rescued ISO‐induced decrease in cardiac ejection fraction and fractional shortening and repressed cardiac hypertrophy. Mechanism study revealed that AldoA repressed the activation of AMP‐dependent protein kinase (AMPK) signaling in a liver kinase B1 (LKB1)‐dependent and AMP‐independent manner. Inactivation of AMPK is a core mechanism underlying AldoA‐mediated promotion of ISO‐induced cardiomyocyte hypertrophy. By contrast, activation of AMPK with metformin and AICAR blocked AldoA function during cardiomyocyte hypertrophy. In summary, our data support the notion that AldoA‐AMPK axis is a core regulatory signaling sensing energetic status and participates in cardiac hypertrophy. HIGHLIGHTSAldolase A (AldoA) is overexpressed in hypertrophic hearts.AldoA promotes cardiomyocyte hypertrophy in vitro.AldoA knockdown represses cardiac hypertrophy in vivo.AMPK is critically involved in AldoA function in cardiac hypertrophy.

• Publication year

  2018

• Venue

  Experimental Cell Research

• Publication date

  2018-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.yexcr.2018.06.009PMID 29902536
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth

  2018cited by this paper
• AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

  2018cited by this paper
• SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy

  2017cited by this paper
• IL-11 is a crucial determinant of cardiovascular fibrosis

  2017cited by this paper
• AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System

  2017cited by this paper
• Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK

  2017cited by this paper
• Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.

  2017cited by this paper
• Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c–SIRT2 axis

  2017cited by this paper
• Aldolase-catalysed stereoselective synthesis of fluorinated small molecules.

  2017cited by this paper
• Revisiting Cardiac Cellular Composition.

  2016cited by this paper
• ALDOA functions as an oncogene in the highly metastatic pancreatic cancer.

  2016cited by this paper
• Therapeutic Potential of AICAR in Attenuating Obesity‐Induced Metabolic, Liver and Kidney Disease

  2016cited by this paper
• Abstract 19668: Caspase Recruitment Domain-Containing Protein 9 Knockout Rescues Heart Function by Reducing Fibrosis and Hypertrophy in a Pressure-Overload Model of Murine Heart Failure

  2016cited by this paper
• Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

  2015cited by this paper
• MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway

  2015cited by this paper
• Resveratrol Treatment of Mice With Pressure-Overload–Induced Heart Failure Improves Diastolic Function and Cardiac Energy Metabolism

  2015cited by this paper
• Endothelial cell metabolism in normal and diseased vasculature.

  2015cited by this paper
• Comparative Proteome Profiling during Cardiac Hypertrophy and Myocardial Infarction Reveals Altered Glucose Oxidation by Differential Activation of Pyruvate Dehydrogenase E1 Component Subunit β.

  2015cited by this paper
• Is Inhibition of Hypertrophy a Good Therapeutic Strategy in Ventricular Pressure Overload?: Inhibition of Hypertrophy, Per Se, May Not Be a Good Therapeutic Strategy in Ventricular Pressure Overload Other Approaches Could Be More Beneficial

  2015cited by this paper
• Inhibition of miR-25 Improves Cardiac Contractility in the Failing Heart

  2014cited by this paper
• AMPK--sensing energy while talking to other signaling pathways.

  2014cited by this paper
• Metformin: from mechanisms of action to therapies.

  2014cited by this paper
• A Thermolabile Aldolase A Mutant Causes Fever-Induced Recurrent Rhabdomyolysis without Hemolytic Anemia

  2014cited by this paper
• Fibroblast-mediated pathways in cardiac hypertrophy.

  2014cited by this paper
• Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production

  2013cited by this paper
• Fibroblast growth factor 21 protects against cardiac hypertrophy in mice

  2013cited by this paper
• Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload.

  2013cited by this paper
• Left Ventricular Failure Produces Profound Lung Remodeling and Pulmonary Hypertension in Mice: Heart Failure Causes Severe Lung Disease

  2012cited by this paper
• Adipose Tissue Inflammation and Adiponectin Resistance in Patients With Advanced Heart Failure: Correction After Ventricular Assist Device Implantation

  2012cited by this paper
• AMP-Activated Protein Kinase Regulation and Biological Actions in the Heart

  2012cited by this paper
• Aldolase is essential for energy production and bridging adhesin-actin cytoskeletal interactions during parasite invasion of host cells.

  2009cited by this paper
• Exogenous NAD Blocks Cardiac Hypertrophic Response via Activation of the SIRT3-LKB1-AMP-activated Kinase Pathway*

  2009cited by this paper
• Cardiac plasticity.

  2008cited by this paper
• Tackling heart failure in the twenty-first century

  2008cited by this paper
• AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol.

  2008cited by this paper
• The failing heart--an engine out of fuel.

  2007cited by this paper
• Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress

  2004cited by this paper
• Increased Adenosine Monophosphate–Activated Protein Kinase Activity in Rat Hearts With Pressure-Overload Hypertrophy

  2001cited by this paper
• from the American Heart Association

  1990cited by this paper

• miRNAS AND TARGET GENES ARE REGULATED POST-TRAINING IN QUARTER HORSE ATHLETES.

  2026cites this paper
• USP13 ameliorates myocardial infarction injury by inhibiting ferroptosis via stabilizing ALDOA

  2025cites this paper
• Transition State Analysis of the Aldol-Like Reaction Catalyzed by NeuB, a Sialic Acid Synthase, Reveals a Stepwise Cationic Mechanism

  2025cites this paper
• Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting ALDOA K42 Lactylation

  2025cites this paper
• Interaction of kidney proteins of normal and hypertensive rats with fragments of renalase peptide RP220.

  2025cites this paper
• The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation

  2024cites this paper
• Scutellarin Protects against Myocardial Ischemia–reperfusion Injury by Enhancing Aerobic Glycolysis through miR-34c-5p/ALDOA Axis

  2024cites this paper
• ALDOA contributes to colorectal tumorigenesis and metastasis by targeting YAP

  2024cites this paper
• Left ventricular myocardial molecular profile of human diabetic ischaemic cardiomyopathy

  2024cites this paper
• Proteomic Characterisation of Heart Failure Reveals a Unique Molecular Phenotype for Hypertrophic Cardiomyopathy

  2024cites this paper
• Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy

  2024cites this paper
• The role of glycolytic metabolic pathways in cardiovascular disease and potential therapeutic approaches

  2023cites this paper
• lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway

  2022cites this paper
• The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2

  2022cites this paper
• IgE and TGF-β Signaling: From Immune to Cardiac Remodeling

  2021cites this paper
• Hsp22 Deficiency Induces Age-Dependent Cardiac Dilation and Dysfunction by Impairing Autophagy, Metabolism, and Oxidative Response

  2021cites this paper
• Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence

  2021cites this paper
• The RING-domain E3 ubiquitin ligase RNF146 promotes cardiac hypertrophy by suppressing the LKB1/AMPK signaling pathway.

  2021cites this paper
• Deciphering the effective combinatorial components from Si-Miao-Yong-An decoction regarding the intervention on myocardial hypertrophy.

  2021cites this paper
• Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome–Associated Cardiomyopathy

  2020cites this paper
• Gö-VIP-22 :

  2020cites this paper
• Mechanisms of action of metformin and its regulatory effect on microRNAs related to angiogenesis.

  2020cites this paper
• ALDOA protects cardiomyocytes against H/R-induced apoptosis and oxidative stress by regulating the VEGF/Notch 1/Jagged 1 pathway

  2020cites this paper
• The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR‐101

  2019cites this paper